Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in multiple sclerosis (MS). Long-term persistence with treatment is important to optimize treatment benefit. This long-term, cohort study was conducted at the Calgary MS Clinic. All consenting adults w...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4395027?pdf=render |
| _version_ | 1819046113838104576 |
|---|---|
| author | Simon Zhornitsky Jamie Greenfield Marcus W Koch Scott B Patten Colleen Harris Winona Wall Katayoun Alikhani Jodie Burton Kevin Busche Fiona Costello Jeptha W Davenport Scott E Jarvis Dina Lavarato Helene Parpal David G Patry Michael Yeung Luanne M Metz |
| author_facet | Simon Zhornitsky Jamie Greenfield Marcus W Koch Scott B Patten Colleen Harris Winona Wall Katayoun Alikhani Jodie Burton Kevin Busche Fiona Costello Jeptha W Davenport Scott E Jarvis Dina Lavarato Helene Parpal David G Patry Michael Yeung Luanne M Metz |
| author_sort | Simon Zhornitsky |
| collection | DOAJ |
| description | Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in multiple sclerosis (MS). Long-term persistence with treatment is important to optimize treatment benefit. This long-term, cohort study was conducted at the Calgary MS Clinic. All consenting adults with relapsing-remitting MS who started either glatiramer acetate (GA) or interferon-β 1a/1b (IFN-β) between January 1st, 1996 and July 1st, 2011 were included. Follow-up continued to February 1st, 2014. Time-to-discontinuation of the initial and subsequently-prescribed DMTs (switches) was analysed using Kaplan-Meier survival analyses. Group differences were compared using log-rank tests and multivariable Cox regression models. Analysis included 1471 participants; 906 were initially prescribed GA and 565 were initially prescribed IFN-β. Follow-up information was available for 87%; 29 (2%) were lost to follow-up and 160 (11%) moved from Southern Alberta while still using DMT. Median time-to-discontinuation of all injectable DMTs was 11.1 years. Participants with greater disability at treatment initiation, those who started treatment before age 30, and those who started between 2006 and 2011 were more likely to discontinue use of all injectable DMTs. Median time-to-discontinuation of the initial DMT was 8.6 years. Those initially prescribed GA remained on treatment longer. Of 610 participants who discontinued injectable DMT, 331 (54%) started an oral DMT, or a second-line DMT, or resumed injectable DMT after 90 days. Persistence with injectable DMTs was high in this long-term population-based study. Most participants who discontinued injectable DMT did not remain untreated. Further research is required to understand treatment outcomes and outcomes after stopping DMT. |
| first_indexed | 2024-12-21T10:39:19Z |
| format | Article |
| id | doaj.art-3f8c8f700f5941a9a09e95a96507aed5 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T10:39:19Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-3f8c8f700f5941a9a09e95a96507aed52022-12-21T19:06:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012382410.1371/journal.pone.0123824Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.Simon ZhornitskyJamie GreenfieldMarcus W KochScott B PattenColleen HarrisWinona WallKatayoun AlikhaniJodie BurtonKevin BuscheFiona CostelloJeptha W DavenportScott E JarvisDina LavaratoHelene ParpalDavid G PatryMichael YeungLuanne M MetzDisease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in multiple sclerosis (MS). Long-term persistence with treatment is important to optimize treatment benefit. This long-term, cohort study was conducted at the Calgary MS Clinic. All consenting adults with relapsing-remitting MS who started either glatiramer acetate (GA) or interferon-β 1a/1b (IFN-β) between January 1st, 1996 and July 1st, 2011 were included. Follow-up continued to February 1st, 2014. Time-to-discontinuation of the initial and subsequently-prescribed DMTs (switches) was analysed using Kaplan-Meier survival analyses. Group differences were compared using log-rank tests and multivariable Cox regression models. Analysis included 1471 participants; 906 were initially prescribed GA and 565 were initially prescribed IFN-β. Follow-up information was available for 87%; 29 (2%) were lost to follow-up and 160 (11%) moved from Southern Alberta while still using DMT. Median time-to-discontinuation of all injectable DMTs was 11.1 years. Participants with greater disability at treatment initiation, those who started treatment before age 30, and those who started between 2006 and 2011 were more likely to discontinue use of all injectable DMTs. Median time-to-discontinuation of the initial DMT was 8.6 years. Those initially prescribed GA remained on treatment longer. Of 610 participants who discontinued injectable DMT, 331 (54%) started an oral DMT, or a second-line DMT, or resumed injectable DMT after 90 days. Persistence with injectable DMTs was high in this long-term population-based study. Most participants who discontinued injectable DMT did not remain untreated. Further research is required to understand treatment outcomes and outcomes after stopping DMT.http://europepmc.org/articles/PMC4395027?pdf=render |
| spellingShingle | Simon Zhornitsky Jamie Greenfield Marcus W Koch Scott B Patten Colleen Harris Winona Wall Katayoun Alikhani Jodie Burton Kevin Busche Fiona Costello Jeptha W Davenport Scott E Jarvis Dina Lavarato Helene Parpal David G Patry Michael Yeung Luanne M Metz Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. PLoS ONE |
| title | Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. |
| title_full | Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. |
| title_fullStr | Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. |
| title_full_unstemmed | Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. |
| title_short | Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. |
| title_sort | long term persistence with injectable therapy in relapsing remitting multiple sclerosis an 18 year observational cohort study |
| url | http://europepmc.org/articles/PMC4395027?pdf=render |
| work_keys_str_mv | AT simonzhornitsky longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT jamiegreenfield longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT marcuswkoch longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT scottbpatten longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT colleenharris longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT winonawall longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT katayounalikhani longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT jodieburton longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT kevinbusche longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT fionacostello longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT jepthawdavenport longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT scottejarvis longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT dinalavarato longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT heleneparpal longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT davidgpatry longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT michaelyeung longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy AT luannemmetz longtermpersistencewithinjectabletherapyinrelapsingremittingmultiplesclerosisan18yearobservationalcohortstudy |